+ Watch IRWD
on My Watchlist
I think this has topped out. Insider trends indicate value no higher than $13
Revenue growth and potential takeover target
Short. Pharma company with revs drying up. Issuing stock.
If it was just me, I probably wouldn't green thumb Ironwood just yet and I definitely wouldn't be buying into this launch. But now I'm working with Portefeuille and his word is law, and he wanted 300 shares at 14.72. There's no question that linaclotide has potential, but falling knife stocks that are navigating drug launches are not my personal style. As usual, I expect my reticence to be proven wrong.
FDA approval of new IBS drug. IBS sufferers have been waiting for this drug and following the FDA approval process in anticipation of it's release.
was the drug approval noticed by anyone?
PDUFA date in next couple months. Drugs has a huge market with less effective competition.
PDUFA coming up
There are currently 2100 IRWD shares in my "fund" with break-even of around 7.48 USD. http://caps.fool.com/Blogs/fund-trades/678775.
With recent Phase 3 FDA testing of their linaclotide drug that has a proven track record resulting in positive performance and a $20bb potential market coupled with no competition (that is until Synergy Pharmaceuticals SGYP drug comes to market), I see tremendous upside in this Bio-tech over the next couple of years.
Another pharm with no earnings.
good starting price.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions